Work

A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer.

Year: 2014

Type: article

Source: PubMed

Authors: Klaus Sahora, Martin Schindl, Irene Kuehrer, Axel Eisenhut, Gregor Werba, Christine Brostjan, Bela Telek, Ahmed Ba'ssalamah, Judith Stift, Sebastian F Schoppmann, Michael Gnant

Institutions: Comprehensive Cancer Center Vienna, Medical University of Vienna

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W36351291

FWCI: 1.829

Cites:

Cited by: 19

Related to: 10